Conventional vaccines, also known as traditional or inactivated vaccines, represent a widely used and effective approach to immunization. These vaccines utilize either weakened or killed forms of the targeted pathogen, such as viruses or bacteria, to stimulate an immune response without causing the disease. Inactivated vaccines typically involve using heat, chemicals, or radiation to deactivate the infectious agent while preserving its immunogenic properties. Live attenuated vaccines use weakened forms of the pathogen, rendering them less virulent but still capable of eliciting a robust immune response. Examples of conventional vaccines include those against diseases like influenza, polio, hepatitis A and B, and pertussis. These vaccines have been instrumental in controlling and preventing a range of infectious diseases, contributing significantly to public health. Conventional vaccines have some limitations, such as the need for cold storage for certain types and the potential for reversion to virulence in live attenuated vaccines. However, ongoing research and advancements continue to optimize these vaccines and explore new technologies for vaccine development. They remain a cornerstone of global vaccination efforts, providing essential protection against a variety of infectious diseases.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States